Hatt S, Antonio-Santos A, Powell C, Vedula S S
International Centre for Eye Health, c/o Cochrane Eyes and Vision Group, London School of Hygiene & Tropical Medicine, Keppel Street, London, UK WC1E 7HT.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD005136. doi: 10.1002/14651858.CD005136.pub2.
Stimulus deprivation amblyopia (SDA) develops due to an obstruction to the clear passage of light, preventing clear formation of an image on the retina for example, cataract, ptosis (droopy eyelid). It is particularly severe and can be resistant to treatment and the visual prognosis is often poor. Stimulus deprivation amblyopia is rare and precise estimates of prevalence difficult to come by; it probably constitutes less than 3% of all cases of amblyopia. In developed countries most patients present under the age of one; in less developed parts of the world presentation is likely to be significantly later than this.The mainstay of treatment is patching of the better-seeing eye but regimes vary, treatment is difficult to execute and results are often disappointing.
The objectives of this review were to evaluate the effectiveness of occlusion treatment for SDA, determine the optimum treatment regime and factors that may affect outcome.
We searched the Cochrane Central Register of Controlled Trials - CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) on The Cochrane Library (2006, Issue 1), MEDLINE (1996 to April 2006), EMBASE (1980 to April 2006) and LILACS (Latin American and Caribbean Literature on Health Sciences) (to November 2004). There were no date or language restrictions.
We aimed to include randomised and quasi-randomised controlled trials of subjects with unilateral SDA defined as worse than 0.2 LogMAR or equivalent. There were no restrictions with respect to age, gender, ethnicity, co-morbidities, medication use, and the number of participants.
Two authors independently assessed study abstracts identified by the electronic searches.
No trials were identified that met the inclusion criteria.
AUTHORS' CONCLUSIONS: It is not possible to conclude how effective treatment for SDA is or which treatment regime produces the best results. There is a need for further study in this area.
剥夺性弱视（SDA）是由于光线清晰传播受阻而导致的，例如白内障、上睑下垂（眼睑下垂），使得视网膜上无法清晰成像。这种弱视特别严重，可能对治疗有抵抗性，视觉预后通常较差。剥夺性弱视较为罕见，难以精确估计其患病率；它可能占所有弱视病例的不到3%。在发达国家，大多数患者在一岁前就诊；在世界较不发达地区，就诊时间可能明显晚于此。治疗的主要方法是遮盖视力较好的眼睛，但治疗方案各不相同，治疗实施困难，结果往往令人失望。
本综述的目的是评估遮盖治疗SDA的有效性，确定最佳治疗方案以及可能影响治疗结果的因素。
我们检索了Cochrane图书馆（2006年第1期）中的Cochrane对照试验中心注册库（CENTRAL）（其中包含Cochrane眼科和视力组试验注册库）、MEDLINE（1996年至2006年4月）、EMBASE（1980年至2006年4月）和LILACS（拉丁美洲和加勒比地区健康科学文献）（至2004年11月）。没有日期或语言限制。
我们旨在纳入单侧SDA患者的随机和半随机对照试验，定义为视力比0.2 LogMAR或等效视力差。在年龄、性别、种族、合并症、药物使用和参与者数量方面没有限制。
两位作者独立评估通过电子检索确定的研究摘要。
未发现符合纳入标准的试验。
无法得出SDA治疗的有效性如何或哪种治疗方案能产生最佳效果。该领域需要进一步研究。
